US Bancorp
MLYS icon

US Bancorp’s Mineralys Therapeutics MLYS Stock Holding History

US Bancorp’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.53K Sell
205
-97
-32% -$2.66K ﹤0.01% 3625
2026
Q1 		$8.18K Buy
302
+221
+273% +$6.48K ﹤0.01% 3421
2025
Q4 		$2.94K Sell
81
-123
-60% -$4.93K ﹤0.01% 3676
2025
Q3 		$7.74K Buy
204
+30
+17% +$649 ﹤0.01% 3397
2025
Q2 		$2.35K Buy
174
+60
+53% +$869 ﹤0.01% 3836
2025
Q1 		$1.81K Buy
114
+96
+533% +$1.1K ﹤0.01% 3905
2024
Q4 		$222 Buy
+18
New +$235 ﹤0.01% 4074

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

US Bancorp's MLYS Position: Q2 2026 in Review

US Bancorp reduced its Mineralys Therapeutics (MLYS) stake by 32% in Q2 2026, selling an estimated $2.66K and leaving 205 shares worth $5.53K. The position accounts for ﹤0.01% of the portfolio, ranked #3625.

US Bancorp first reported a position in MLYS in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.18K in Q1 2026. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • US Bancorp held 205 shares of Mineralys Therapeutics worth $5.53K as of Q2 2026.
  • US Bancorp sold 97 Mineralys Therapeutics shares in Q2 2026, an estimated $2.66K.
  • Mineralys Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3625 holding.
  • US Bancorp first reported a position in Mineralys Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • US Bancorp's Mineralys Therapeutics position peaked at $8.18K in Q1 2026.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.